Welcome to Nanjing Byabscience    HOTLINE: 800-880-8748 |
Location: Home > Products > Primary Antibodies > Polyclonal antibody

CIITA Polyclonal Antibody

Polyclonal antibody

Specification

BYab-01611

  • 50UL $180 100UL $255
  • Delivery: In Stock

Product introduction Experimental scheme Citation Related products

Product introduction>

Host
Reactiveness
Use
Molecular weight (DA)
123kD
Immunogen
The antiserum was produced against synthesized peptide derived from human CIITA. AA range:706-755
Specificity
CIITA Polyclonal Antibody detects endogenous levels of CIITA protein.
Source
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Dilution rate
Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications.
Purification process (Immunogen)
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
1 mg/ml
Background
class II major histocompatibility complex transactivator(CIITA) Homo sapiens This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardi
Function
disease:Defects in CIITA are a cause of bare lymphocyte syndrome type 2 (BLS2) [MIM:209920]; also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency. BLS2 is a severe combined immunodeficiency disease with early onset. It is characterized by a profound defect in constitutive and interferon-gamma induced MHC II expression, absence of cellular and humoral T-cell response to antigen challenge, hypogammaglobulinemia and impaired antibody production. The consequence include extreme susceptibility to viral, bacterial and fungal infections.,function:Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. No DNA binding of in vitro translated CIITA was detected. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II prom
Gene Name
CIITA
Protein name
MHC class II transactivator
Abbreviation
CIITA
Other name
CIITA; MHC2TA; MHC class II transactivator; CIITA
Fields
>>Antigen processing and presentation;>>Toxoplasmosis;>>Tuberculosis;>>Influenza A;>>Primary immunodeficiency
Human gene ID
4261
Human protein sequence Database
P33076
Mouse gene ID
12265
Mouse protein sequence database
P79621
Rat gene ID
Rat protein sequence database
Cellular localization
Nucleus . Nucleus, PML body . Recruited to PML body by PML.
Tissue expression
Storage
-20°C/1 year

Experimental scheme>

Procedure

Citation(0)>

成功添加到购物车

查看购物车 继续购物

CIITA Polyclonal Antibody

亮暗模式切换
X

Online
Service

Online Service
08:30 - 17:30

service hotline

Service
Hotline

Customer service hotline

800-880-8748
Customer service hotline

扫码

Scan
Wechat

微信二维码 Scan wechat
返回顶部 TOP